Table 1 Characteristics of patients at enrolment into the IPF-PRO Registry (n = 662)
Age, years | 70 (65, 75) |
Male | 496 (74.9) |
White | 623 (94.1) |
Body mass index, kg/m2 | 29.0 (26.0, 32.4) |
Private insurance | 420 (66.4) |
Current or former smoker | 446 (68.4) |
Oxygen use with activity | 217 (34.1) |
Oxygen use at rest | 125 (19.6) |
Serologic testing reported at enrolment At least one abnormal serologic test reported | 184 (27.8) 161 |
Receiving immunosuppressive or cytotoxic medications | 5 (0.8) |
Receiving nintedanib or pirfenidone | 352 (54.0) |
Surgical lung biopsy performed prior to enrolment | 176 (30) |
Bronchoscopy performed within 12 months of enrolment | 60 (10.3) |
Prior diagnosis of IPF (confirmed at the enrolling centre) | 301 (45) |
Diagnostic criteriaa | |
Definite IPF | 437 (68.8) |
Probable IPF | 141 (22.2) |
Possible IPF | 57 (9.0) |
History of coronary artery disease or congestive heart failure | 203 (31.2) |
History of pulmonary hypertension | 51 (7.9) |
Emphysemab | 71 (11.2) |
Prior hospitalisation (any) | 171 (29.3) |
Respiratory related | 106 (18.2) |
Non-respiratory related | 86 (14.8) |
Symptom onset to confirmed diagnosis of IPF at enrolling center, months | 14 (7, 29) |
Distance to enrolling centre, miles | 40 (16, 109) |
FVC, % predicted | 69.6 (60.1, 79.9) |
DLco, % predicted | 41.7 (32.2, 50.1) |
Prior respiratory hospitalisation | 106 (18.2) |
1 | 84 (12.7) |
2 | 18 (2.7) |
3 | 3 (0.5) |
4 | 1 (0.2) |
Composite physiologic index | 53.2 (45.7, 60.0) |
GAP stage | |
I | 146 (26.4) |
II | 306 (55.2) |
III | 102 (18.4) |